Form 4 for INSM INSMED Inc
Accepted 2025-07-23 00:00:00 ET · period of report 2025-07-21 · accession 0001628280-25-035755 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-07-23 | 2025-07-21 | INSM | Bonstein Sara | CFO | M - OptEx | $30.63 | +47.9K | 131.9K | +57% | +$1.47M |
| DM | 2025-07-23 | 2025-07-21 | INSM | Bonstein Sara | CFO | S - Sale+OE | $102.67 | -58.4K | 73.5K | -44% | -$6.00M |
| DM | 2025-07-23 | 2025-07-21 | INSM | Bonstein Sara | CFO | M - OptEx | $0.00 | -47.9K | 8,580 | -85% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-21 | M | A | 3,443 | $26.46 | 87,460 | D | — | — | |
| 2 | Common | Common Stock | 2025-07-21 | M | A | 11,455 | $28.88 | 98,915 | D | — | — | |
| 3 | Common | Common Stock | 2025-07-21 | M | A | 15,890 | $29.13 | 114,805 | D | — | — | |
| 4 | Common | Common Stock | 2025-07-21 | M | A | 17,100 | $34.03 | 131,905 | D | — | — | |
| 5 | Common | Common Stock | 2025-07-21 | S | D | 32,090 | $102.38 | 99,815 | D | — | — | (F2) This is the weighted average sales price representing 32,090 shares sold at prices ranging from $101.77 to $102.76 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 6 | Common | Common Stock | 2025-07-21 | S | D | 26,310 | $103.03 | 73,505 | D | — | — | (F3) This is the weighted average sales price representing 26,310 shares sold at prices ranging from $102.77 to $103.37 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 7 | Derivative | Stock Option (right to buy) | 2025-07-21 | M | D | 15,890 | $0.00 | 47,670 | D | $29.13 · — to 2034-01-04 | 15,890 Common Stock | (F5) The options become exercisable based on the following vesting schedule: 25% vest on the first anniversary of the grant date and an additional 12.5% vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| 8 | Derivative | Stock Option (right to buy) | 2025-07-21 | M | D | 17,100 | $0.00 | 0 | D | $34.03 · — to 2031-01-07 | 17,100 Common Stock | (F4) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. |
| 9 | Derivative | Stock Option (right to buy) | 2025-07-21 | M | D | 11,455 | $0.00 | 0 | D | $28.88 · — to 2030-02-03 | 11,455 Common Stock | (F4) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. |
| 10 | Derivative | Stock Option (right to buy) | 2025-07-21 | M | D | 3,443 | $0.00 | 8,580 | D | $26.46 · — to 2031-05-12 | 3,443 Common Stock | (F4) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. |